Management of Methotrexate-Induced Pancytopenia

Introduction to Management

The American Academy of Dermatology recommends immediately discontinuing methotrexate and initiating leucovorin (folinic acid) rescue therapy as the first-line management approach for methotrexate-induced pancytopenia, defined as WBC <3,500 cells/mm³, hemoglobin <11 g/dL, and platelets <150,000 cells/mm³ 1, 2, 3
Discontinue methotrexate immediately upon detection of pancytopenia, and administer leucovorin (folinic acid) as the antidote for hematologic toxicity, with an initial dose of up to 100 mg/m² IV if methotrexate levels are unknown 1, 2, 3, 4

Administer leucovorin (folinic acid) as soon as possible, as time is critical—leucovorin is most effective when initiated within hours of the last methotrexate dose, with efficacy decreasing dramatically after 24 hours 3
Continue leucovorin until hematological abnormalities have resolved 2

For severe pancytopenia (WBC <2,000 cells/mm³, Hb <10 g/dL, platelets <50,000 cells/mm³), admit to hospital immediately for close monitoring and infection prevention, and initiate leucovorin rescue therapy (up to 100 mg/m² IV) 2, 3
Consider granulocyte colony-stimulating factor (G-CSF) such as filgrastim at 5 μg/kg daily subcutaneously to accelerate myeloid recovery in severe pancytopenia 2, 3

Maintain adequate hydration to improve renal elimination of methotrexate, and continue urine alkalinization with sodium bicarbonate to prevent methotrexate precipitation in renal tubules 2
Monitor complete blood count frequently until recovery, and implement infection prevention measures for patients with severe neutropenia 1, 2

Renal insufficiency is a significant risk factor, present in 30% of cases, and dosing errors are present in 28% of cases 4
Lack of folate supplementation is a risk factor, present in 15% of cases, and drug interactions, particularly with trimethoprim-sulfamethoxazole, NSAIDs, or penicillins, should be considered 4, 1, 2

Ensure folic acid supplementation (1-5 mg daily except on methotrexate day) for all patients on methotrexate therapy to prevent pancytopenia 4, 5, 1, 2
Monitor CBC, liver function tests, and renal function tests at baseline, within 1-2 months of starting therapy, and every 3-4 months thereafter to detect potential toxicity early 5, 1, 2

Elderly patients are at substantially higher risk for methotrexate toxicity due to age-related decline in renal function, decreased folate stores, and polypharmacy, with a higher absolute risk of thiopurine-related malignancy and infections with immunosuppressive therapy, according to the American Gastroenterological Association 6
The American Academy of Dermatology recommends evaluating renal impairment as a contributing risk factor, as 85% of methotrexate is renally excreted, and drug interactions such as trimethoprim-sulfamethoxazole, NSAIDs, penicillins, salicylates, or probenecid can decrease renal tubular excretion of methotrexate 7

In elderly patients who have experienced pancytopenia, the American Gastroenterological Association strongly considers alternative disease-modifying agents rather than restarting methotrexate, due to the higher absolute risk of malignancy and serious infections 6